Neovasc (NVCN) Stock: Climbing On Data Publication

Neovask Inc NVCN Stock NewsNeovasc Inc (NASDAQ: NVCN) is flying early on in the trading session this morning, and for good reason. The company announced that data from its REDUCE study has been published in a peer-reviewed journal. Of course, the news excited investors who are sending the stock on a run for the top. Today, we’ll talk about:

  • The data publication;
  • what we’re seeing from NVCN stock; and
  • what we’ll be watching for ahead.

NVCN Climbs On Data Publication 

As mentioned above, Neovasc is having an incredibly strong start to the trading session this morning after news broke taht data was published in a peer reviewed journal. In a press release issued early this morning, the company announced the publication of the manuscript, “Safety and efficacy of the Reducer: a multicenter clinical registry – REDUCE study.” The data was published in the International Journal of Cardiology.




During the study, the Reducer by NVCN was evaluated using a real-world cohort of 141 patients in three high-volume medical centers in Milan, Tel Aviv and Antwerp. During the study, the researchers worked to evaluate the efficacy of the Reducer in improving the quality of life and reducing symptoms of angina pectoris in 141 consecutive patients suffering from coronary artery disease and crhonic refractory angina.

In the release, the company said that the investigator demonstrated that the treatment was safe and significantly reduced the severity of angina. This was measured by the Canadian Cardiovascular Scoiety classificantion. Overall, results showed that 81% of patients experienced improvements in their angina severty by at least one CSS class and 45% of patients became free of any limiting angina as they improved by 2 or more grades. In a statement, Fred Colen, President and CEO at NVCN, had the following to offer:

The publication is another ‘real-world,’ non-randomized study which demonstrates clinical results in an additional 141 enrolled patients, that are remarkably consistent with the results of the COSIRA randomized sham-controlled clinical trial. This recent manuscript published in the International Journal of Cardiology is a testament to the benefits of the Reducer as a safe device, which can provide substantial qualify of life improvements in patients with refractory angina, who do not have other suitable treatment alternatives… We are very pleased to have this data published in such a highly-regarded journal.

What We’re Seeing From The Stock 

One of the first lessons that we learn when we start to dig into the market is that the news casues moves. In the case of Neovasc, the news proved to be overwhelmingly positive. After all, strong clinical data adds further validity to the company’s work surrounding the Reducer. So, it comes as no surprise that excited investors are pushing the stock toward the top in the market this morning. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:58), NVCN is trading at $0.038 per share after a gain of $0.0053 or 15.96% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on NVCN. In particular, we’re interested in following the story surrounding the ongoing work with regard to the Reducer. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required


Add Comment